company background image
A221

U2Bio XKON:A221800 Stock Report

Last Price

₩27.00k

Market Cap

₩51.3b

7D

-2.2%

1Y

127.8%

Updated

13 May, 2022

Data

Company Financials
A221800 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

A221800 Stock Overview

U2Bio CO. LTD. provides medical IT solutions in South Korea.

U2Bio Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for U2Bio
Historical stock prices
Current Share Price₩27,000.00
52 Week High₩34,000.00
52 Week Low₩9,100.00
Beta0
1 Month Change-9.24%
3 Month Change-14.29%
1 Year Change127.85%
3 Year Change107.69%
5 Year Change47.95%
Change since IPO70.35%

Recent News & Updates

Shareholder Returns

A221800KR HealthcareKR Market
7D-2.2%-0.8%-3.3%
1Y127.8%-38.5%-14.3%

Return vs Industry: A221800 exceeded the KR Healthcare industry which returned -38.5% over the past year.

Return vs Market: A221800 exceeded the KR Market which returned -14.3% over the past year.

Price Volatility

Is A221800's price volatile compared to industry and market?
A221800 volatility
A221800 Average Weekly Movement5.7%
Healthcare Industry Average Movement5.7%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A221800 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A221800's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009n/aJin-Tae Kimhttps://www.u2bio.co.kr

U2Bio CO. LTD. provides medical IT solutions in South Korea.

U2Bio Fundamentals Summary

How do U2Bio's earnings and revenue compare to its market cap?
A221800 fundamental statistics
Market Cap₩51.31b
Earnings (TTM)₩0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A221800 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩0
Earnings₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A221800 perform over the long term?

See historical performance and comparison

Valuation

Is U2Bio undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether U2Bio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as U2Bio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is U2Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as U2Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has U2Bio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.6%

Historical Healthcare annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, U2Bio has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Financial Health

How is U2Bio's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse U2Bio's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. U2Bio has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Dividend

What is U2Bio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A221800's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A221800's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A221800's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A221800's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A221800 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jin-Tae Kim (57 yo)

no data

Tenure

Mr. Kim, Jin-Tae has been Chief Executive Officer of U2Bio CO. LTD. November 2009.Mr. Kim served as the President of UBCare Co., Ltd. and served as its Chief Executive Officer from December 1994 to Octobe...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

U2Bio CO. LTD.'s employee growth, exchange listings and data sources


Key Information

  • Name: U2Bio CO. LTD.
  • Ticker: A221800
  • Exchange: XKON
  • Founded: 2009
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: ₩51.314b
  • Shares outstanding: 1.90m
  • Website: https://www.u2bio.co.kr

Location

  • U2Bio CO. LTD.
  • 68, Geoma-ro
  • Songpa-gu
  • Seoul
  • 138-818
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/13 00:00
End of Day Share Price2022/05/12 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.